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Abstract: Cardiometabolic disease is recognized as the predominant cause of global mortality and
healthcare expenditure. Whilst pharmaceutical interventions are effective in the short term, their
long-term efficacy remain equivocal and their associated side-effects are concerning. Owing to
their high levels of anthocyanins, Montmorency tart cherries and blueberries have been cited as
potentially important natural treatment/preventative modalities for cardiometabolic disease. This
study proposed a randomized controlled trial, aims to test the effects of consumption of Montmorency
tart cherry and blueberry juice on cardiometabolic outcomes compared to placebo. This 20-day,
parallel, single-blind, randomized, placebo-controlled trial will recruit 45 individuals, who will be
assigned to receive 60 mL per day of either Montmorency tart cherry juice, blueberry juice or a
cherry/blueberry flavoured placebo. The primary study outcome is the between-group difference
in systolic blood pressure from baseline to post-intervention. Secondary outcome measures will be
between-group differences in anthropometric, energy expenditure and substrate oxidation (during
rest and physical activity), haematological, blood pressure/resting heart rate, psychological wellbeing
and sleep efficacy indices. Statistical analysis will be conducted on an intention-to-treat basis. This
study has been granted ethical approval by the University of Central Lancashire, Health Research
Ethics Committee (ref: HEALTH 0016) and formally registered as a trial. Dissemination of the study
findings from this investigation will be through publication in a leading peer-reviewed journal.
Keywords: tart cherry; blueberry; cardiovascular disease; blood pressure; metabolic health
Strengths and Limitations of this Study
- This study will be the first randomized placebo-controlled trial to examine the effec-
tiveness of both Montmorency tart cherry and blueberry juice on cardiometabolic
outcomes.
- Primary and secondary outcomes measures are central to the treatment of cardiometab-
olic disease and its comorbidities.
1. Introduction
Cardiovascular conditions, type 2 diabetes mellitus and other associated cardiometabolic
disease modalities are recognized as the predominant causes of global mortality and health-
care expenditure [1]. Cardiometabolic syndrome is characterized by a range of symptoms
including hypertension, obesity, insulin resistance, atherogenic dyslipidaemia, low high-
density lipoproteins, high triglycerides, high levels of adiposity, high body mass index,
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large waist to hip ratio and poor glucose regulation [2]. To date, different pathophysio-
logical biomarkers have emerged within the literature, with indices of oxidative stress,
nitric oxide and inflammation being cited as key mechanisms that promote the clinical
manifestation of cardiometabolic disease [3,4].
Traditional treatment modalities for cardiometabolic disease habitually include angiotensin-
converting enzyme inhibitors, betablockers, calcium antagonists, diuretics, and lipid-
lowering drugs [5]. However, whilst administration of these medications is effective in the
treatment, postponement and prevention of cardiometabolic disease, their longitudinal
effects and cost-effectiveness has yet to be corroborated [6], and significant negative side-
effects remain common [7]. These side effects paired with recent findings show that globally
84% of adults over the age of 57 are currently taking at least one prescription medication per
day and emphasize that natural cost-effective remedies are necessary for the management
of cardiometabolic disease [8].
The efficacy of improved habitual dietary practice on cardiometabolic health is unam-
biguous, to the extent that medical organizations recommend this as the primary approach
for the prevention and management of cardiometabolic disease [9]. This therefore pro-
vides a clear rationale for the adoption of dietary interventions; and indeed, moderate
and sustainable improvements in health, based around effective nutritional approaches
are more noteworthy, cost-effective and safer than ‘high risk’ pharmacological drugs con-
sumed in the short-term to treat and prevent metabolic disease [10]. Diets rich in fruits
and vegetables have been shown to provide protection from cardiometabolic disease [11].
However, establishing and maintaining a dietary pattern high in fruits and vegetables over
a sustained duration is difficult to accomplish [12]; therefore, dietary supplementation
represents a potentially more appealing treatment and prevention modality.
Anthocyanins are abundant in many fruits and vegetables and impart the dark colours
found in various fruit and vegetable groups [13]. There is growing evidence that antho-
cyanins may confer significant improvements to cardiometabolic health [14] and Mont-
morency tart cherries, blueberries, strawberries, cranberries and blackcurrants (i.e., dark
fruits) [15] in particular have been shown to possess high anthocyanin contents [16], al-
though the majority of peer-reviewed literature has focused on tart cherries. Importantly,
supplementation of anthocyanin rich tart cherries has been shown to effectively combat
oxidative stress [17,18] and inflammation [18–20] and that blackberry supplementation
promotes increased fat oxidation rates [21]. Improved fat oxidation rates during rest and
physical activity are linked to long-term changes in body mass and composition allied
to improvements in insulin sensitivity [22]. Therefore, an increased capacity to oxidize
fat at rest and during moderate physical activity, instigated via anthocyanin rich supple-
mentation, may be advantageous for yielding improvements in body composition and
insulin control. Importantly, the aforementioned anti-inflammatory, anti-oxidative and
substrate trafficking effects, mediated through supplementation of anthocyanin rich fruits,
conveniently target the underlying chronic low-grade inflammation, pro-oxidant and lipid
attenuating status that is central to cardiometabolic pathophysiology [23].
However, the findings from parallel trials investigating the effects of anthocyanin
rich fruit supplementation on cardiometabolic outcomes have yielded equivocal findings.
Some studies exploring the effects of tart cherry juice supplementation have shown no
effect on cardiometabolic indices of blood pressure, triglycerides, insulin tolerance or
cholesterol [24–27] and some have revealed improvements in systolic blood pressure and
low-density lipoprotein (LDL) cholesterol [28,29]. Studies exploring the efficacy of other
anthocyanin rich supplements present a similarly equivocal picture, with some demon-
strating positive effects on cardiometabolic outcomes [30–34] and some showing no such
effects [35–38]. At the current time, there has yet to be any randomized intervention stud-
ies, comparatively examining the efficacy of different anthocyanin rich fruit supplements
on cardiometabolic outcomes. With some food biochemical investigations showing that
anthocyanin contents in dark fruits such as blueberries are as high or even greater than in
tart cherries [16], further such investigations may be of both practical and clinical relevance.
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1.1. Aims and Objectives
The aim of the current study was to investigate the influence of 20 days of twice daily
Montmorency tart cherry or blueberry juice supplementation on cardiometabolic health
indices in healthy adults compared to placebo. The primary objective of this randomized
trial is to examine the influence of the tart cherry and blueberry supplements on systolic
blood pressure relative to placebo. Its secondary objectives are to assess if tart cherry juice
and blueberry supplementation impacts on other risk factors for cardiometabolic disease.
1.2. Hypotheses
In relation to the primary outcome, both Montmorency tart cherry and blueberry
supplement groups will mediate reductions in systolic blood pressure compared to the
placebo, but no differences will be observed between supplement groups. Furthermore, for
the secondary outcomes, the Montmorency tart cherry and blueberry groups will produce
improvements in cardiometabolic health parameters compared to the placebo, but there
will be no differences between the two supplement groups.
2. Materials and Methods
Described according to the updated guidelines for reporting parallel group random-
ized trials [39].
2.1. Study Design and Setting
This investigation represents a 20-day parallel, single-blind (blinded to participant)
randomized placebo-controlled trial (Figure 1). After screening for eligibility and enrolment,
participants will be familiarized with the testing equipment, questionnaires and procedures.
Participants will then be randomized by a computer program (Random Allocation Software)
to either a Montmorency tart cherry, blueberry or placebo group. Cardiometabolic health
and other variables, as described in detail below, will be assessed at baseline and after
20 days (post-intervention). In agreement with previous trials of cardiometabolic health, the
primary outcome measure will be the between-group difference in systolic blood pressure
from baseline to post-intervention [27]. Secondary outcome measures will be between-
group differences in anthropometric, energy expenditure and substrate oxidation (during
rest and physical activity), haematological, blood pressure/resting heart rate, psychological
wellbeing and sleep efficacy indices. All experimental visits will take place in the morning
and be undertaken in a ≥10 h fasted state. Participants will also be required to arrive
hydrated and to avoid strenuous exercise, alcohol, and nutritional supplements for 24 h
and caffeine for 12 h prior.
2.2. Participants
2.2.1. Inclusion Criteria
- Eighteen years of age and above
- Non-smoker
- BMI < 30
- Able to give informed consent
2.2.2. Exclusion Criteria
- Pregnancy
- Sixty-five years of age and above
- Diabetes or any other metabolic/uncontrolled hypertensive conditions
- Food allergies to cherries or blueberries
- Habitual consumption of blueberries/cherries and/or blueberry/cherry products
- Not regularly taking medication or antioxidant supplements
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2.2.3. Sample Size
Power calculations were performed for the primary outcome variable, i.e., the between
groups difference in systolic blood pressure. This showed that a total sample size of 45
will be necessary to provide 80% power to detect a minimally important clinical difference
(MCID) of 6 mmHg between groups [40], with a projected standard deviation of 5.5 mmHg
in each group [41], accounting for a loss t follow up rate of 10%.
2.3. Recruitment
It is expected that p rticipants will predominantly be recruited from the UK city of
Preston and its surround ng areas. Recruitment will be undertaken by poster promotion
across the university campus, at l cal workpla es and also through ad rtisement on
social media. Intereste individuals will be a e to contact the research team for further
study information and to ask any questions assoc ated with participation in the study.
Participants will be invited to at end an eligibility, enrolment and familiarization session
at the University of Central Lancashire. Written informed consent will be obtained from
those willing to take part.
2.4. Dietary Intervention
After the conclusion of their baseline data collection session, participants will be pro-
vided with either Montmorency tart cherry, blueberry or placebo concentrate. Participants
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will be required to consume 30 mL of supplement diluted in 100 mL of water twice daily:
once in the morning and again in the evening [27]. All supplementations will be kept
refrigerated throughout. According to the manufacturer (ActiveEdge, Hanwell, UK), a
30 mL dose of Montmorency tart cherry concentrate (energy: 102 kcal, carbohydrates: 25 g
of which sugars: 18 g, protein: 1.10 g and fibre: 2.6 g) is equivalent to approximately 320 mg
of anthocyanins. Similarly, taking into account the manufacturers (ActiveEdge, Hanwell,
UK) guidelines, a 30 mL dose of blueberry concentrate (energy: 103 kcal, carbohydrates:
22 g of which sugars: 22 g, protein: 0.2 g and fibre: 0.2 g) is equivalent to approximately
387 mg of anthocyanins. Preparation of the placebo will involve mixing 100% un-flavoured
maltodextrin carbs (MyProtein, Cheshire, UK) into drinking water using a magnetic stirrer
(Stuart Scientific, UK) and stir bar (Fisher Scientific, Waltham, MA, USA). Then, 666 g of
maltodextrin will be added to water to create a litre of placebo concentrate, working out
as 20 g of maltodextrin per 30 mL serving, closely matching the Montmorency tart cherry
or blueberry concentrates. Even amounts of red and black food colouring will be added
to match the colour of the Montmorency tart cherry concentrate and even amount of red,
blue and black colouring to match the colour of the blueberry supplement. Either cherry
or blueberry flavdrops (1 mL) (MyProtein, UK) will then added to match the required
flavour. A 30 mL dose of placebo concentrate (100 kcal, carbohydrates 25 g of which sugars:
0 g, protein: 0 g and fibre 0 g) contains 0 mg of anthocyanins. This method of placebo
preparation has been shown by previous intervention trials to provide an effective blinding
strategy [42].
Throughout the study, the participants will be encouraged to maintain their habit-
ual diet and exercise routines and asked to refrain from consuming any multivitamin
or antioxidant supplements [24]. For their post-intervention data collection session, all
participants will be asked to return any un-used supplementation to the laboratory in order
to determine the actual amount of supplement/placebo that was consumed (mL), and the
% compliance in each group will be reported. Furthermore, in order to examine blinding
efficacy, each participant will be asked which trial arm they felt that they had been allocated
to at the conclusion of their post-intervention data collection session. In both groups loss to
follow up will be monitored, as will be any adverse events.
2.5. Data Collection
2.5.1. Laboratory Visit Data
All measurements will be made at University of Central Lancashire’s physiology
laboratory and will be undertaken in an identical manner on two occasions, i.e., baseline
and post-intervention. The laboratories housed by the University of Central Lancashire are
fully accredited by the British Association for Sport and Exercise Sciences, illustrating that
they have undergone meticulous inspection and evidenced that; all instrumentation is well
maintained in terms of reliability, validity and routine servicing, staff have the appropriate
professional and vocational qualifications and that the requisite operational procedures for
health and safety are met.
2.5.2. Anthropometric Measurements
Anthropometric measures of mass (kg) and stature (m) (without shoes) will be used
to calculate body mass index (kg/m2). Stature will be measured using a stadiometer (Seca,
Hamburg, Germany) and mass will be measured using weighing scales (Seca 875, Ham-
burg, Germany). In addition, body composition will be examined using a phase-sensitive
multifrequency bioelectrical impedance analysis device (Seca mBCA 515, Hamburg, Ger-
many) [43], allowing percentage body fat (%) and fat mass (kg) to be quantified. Finally,
waist circumference will be measured at the midway point between the inferior margin
of the last rib and the iliac crest and hip circumference around the pelvis at the point of
maximum protrusion of the buttocks, without compressing the soft tissues [44], allowing
the waist-to-hip ratio to be quantified.
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2.5.3. Energy Expenditure and Substrate Oxidation
Respiratory gases will be collected throughout testing using a gas analysis system
(MetaLyser 3B system, Cortex Biophysic, Leipzig, Germany). The University of Central
Lancashire laboratory is air-conditioned, allowing a fixed ambient temperature of 20 ◦C to
be maintained throughout. To quantify resting energy expenditure and substrate oxidation,
participants will lay supine for a period of 20 min and data will be extracted and averaged
over the final 17 min [45]. Resting fat and carbohydrate oxidation rates (g/min) will be
quantified using established stoichiometric formulae (Equations (1) and (2)), assuming
negligible protein utilization [46]. The amounts of each substrate expressed in g/min will be
multiplied by 4 for carbohydrates and by 9 for fats [47]. These values will then be summed
and subsequently multiplied by 1440 (i.e., the number of minutes per day), allowing daily
energy expenditure (kcal/day) to be quantified and the percentage contribution (%) of each
substrate to resting energy expenditure to be calculated.
In addition, carbohydrate and fat oxidation rates (g/min) and also the percentage
contribution (%) of these substrates to energy expenditure will also be examined, during
moderate intensity physical activity. Participants will walk on a treadmill (hp Cosmos
Pulsar, Nussdorf, Germany) at a velocity of 4.5 km/h for a period of 6 min [47]. This
walking velocity has reliably been shown to correspond to moderate exercise intensities [48].
Data will be averaged over the last minute of the 6 min test [47].
Carbohydrate (g/min) = 4.344 × VCO2 − 3.061 × VO2 (1)
Fat (g/min) = 1.695 × VO2 − 1.701 × VCO2 (2)
2.5.4. Haematological Testing
Capillary blood samples will be collected by finger-prick using a disposable lancet
after cleaning with a 70% ethanol wipe. Capillary triglyceride, total cholesterol and glucose
levels (mmol/L) will immediately be obtained using three handheld analysers (MulticareIn,
Multicare Medical, Washington, DC, USA) and capillary haemoglobin levels (g/L) using a
single handheld analyser (HemoCue, Ängelholm, Sweden). From these outcomes, LDL
cholesterol (mmol/L) will firstly be quantified using the Anandarja et al., [49] formula using
total cholesterol and triglycerides as inputs. In addition, high-density lipoprotein (HDL)
cholesterol (mmol/L) will also be calculated by re-arranging the Chen et al., [50] equation to
make HDL the product of the formulae. Both of these approaches have been shown to have
excellent similarity to their associated lipoprotein values examined using immunoassay
techniques r = 0.948–0.970 [47,48]. The ratios between total and HDL cholesterol and
between LDL and HDL cholesterol levels will also be determined in accordance with
Millán et al. [51].
2.5.5. Blood Pressure and Resting Heart Rate
Blood pressure and resting heart rate measurements will be undertaken in an upright
seated position at the end of the above-described resting energy expenditure test. Both
peripheral measures of systolic and diastolic blood pressure and resting heart rate will be
measured via a non-invasive, automated blood pressure monitor (OMRON M2, Kyoto,
Japan), adhering to the recommendations specified by the European Society of Hyperten-
sion [52]. Three readings will be undertaken, each separated by a period of 1 min [53], and
the mean of the last 2 readings used for analysis.
2.5.6. Questionnaires
Sleep quality is diminished in patients with cardiometabolic disease [54] and intake
of dietary polyphenols [55], and supplementation of Montmorency tart cherry has been
demonstrated to enhance sleep quality and symptoms of insomnolence [56,57]. Therefore,
general sleep quality will be examined using the Pittsburgh sleep quality index [58],
daytime sleepiness using the Epworth Sleepiness Scale [59] and symptoms of insomnolence
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via the Insomnia Severity Index [60]. These questionnaires will be utilized cooperatively to
provide a collective representation of sleep efficacy.
Furthermore, psychological wellbeing is lower in those with cardiometabolic dis-
ease [61] and a high intake of dietary polyphenols has been shown to enhance indices of
psychological wellbeing [62]. Therefore, general psychological wellbeing will be examined
using the COOP WONCA questionnaire [63], depressive symptoms using the Beck De-
pression Inventory [64] and state/trait anxiety with the State Trait Anxiety Inventory [65].
Once again, these scales will be utilized conjunctively to provide a collective depiction of
psychological wellbeing.
2.6. Data Management
The collection and storage of data will adhere to the standard requirements of the
Data Protection Act 2018. Data will be entered onto electronic spreadsheets, which will
be stored on a secure university server using Microsoft OneDrive. All data will be treated
confidentially and anonymized for evaluation. Hard copies of data and documents will
be kept in a locked and secure filing cabinet for the duration of the study. Following
completion of the study, data will be transferred to the University of Central Lancashire
Research Data Archive (CLOK), where it will be kept for 5 years. Hard copies will be
disposed of confidentially and electronic data deleted after this period of time.
2.7. Statistical Analysis
All experimental data (with the exception of the subjective ratings of trial arm alloca-
tion) will be continuous and will therefore be presented as mean and 95% CIs. Statistical
analysis of all baseline variables will be conducted to compare the three groups at baseline
using linear mixed models, with groups modelled as a fixed factor and random intercepts
by participants. All analyses of the intervention-based data will be performed using an
intention to treat basis, and all randomized participants will be included in the final anal-
ysis as far as data collected will allow. Furthermore, in order to determine the effects of
the intervention on all of the outcome measures, differences between the three groups
will be examined using linear mixed models with group modelled as a fixed factor and
random intercepts by participants adopted, adjusted for baseline values modelled as a
continuous fixed covariate. For linear mixed models the mean difference (b), t-value and
95% confidence intervals of the difference will be presented. Finally, blinding efficacy will
also be examined using a chi-squared (X2) test. All analyses were conducted using SPSS v27
(IBM, SPSS), and statistical significance for all analyses was accepted as the p ≤ 0.05 level.
3. Ethics and Dissemination
This study has been granted ethical approval by the University of Central Lancashire
Health Research Ethics Committee (ref: HEALTH 0016) and formally registered as a trial
(NCT04177238). Any required alterations to the experimental protocol will be sent for
re-review/approval by the research ethics committee and amended at the trial registry.
Participants who express a desire to see a summary of the trial findings will be provided
with such information when the data have been analysed. Dissemination of the study
findings from this investigation will be through publication in a leading peer-reviewed
journal, and presentation at both national and international scientific conferences.
4. Conclusions and Limitations
The placebo randomized trial described in this protocol paper will explore the ef-
fects of both Montmorency tart cherry and blueberry juice on the primary and secondary
outcomes pertinent to the aetiology of cardiometabolic disease and its comorbidities. As car-
diometabolic conditions, they are recognized as the predominant causes of global mortality
and healthcare expenditure, and the findings may provide important clinical information
regarding the potential prophylactic role that anthocyanin rich fruit supplementation may
play in healthy individuals.
Int. J. Environ. Res. Public Health 2021, 18, 9759 8 of 11
However, like all research, the trial protocol described in this paper is not without
limitations. Firstly, in order to minimize both inter and intra-subject variability, the pro-
posed protocol will involve examining participants after an overnight fast. Therefore, it
is possible that data collection will not capture the peak vasomodulatory effects of the
experimental supplementation. Importantly, participants will be given instructions re-
garding storage/intake, and compliance to each intervention group will be quantified as
any un-used supplementation will be returned and measured. However, it is ultimately
not possible to control for or determine how participants actually stored or when chrono-
logically they consumed their supplementation. Furthermore, although blood pressure
will be quantified using established techniques in accordance with the European Soci-
ety of Hypertension, measures will be obtained at a single time point in a laboratory
environment. Therefore, 24 h continuous blood pressure monitoring may be more effi-
cacious and representative of normal daily-living conditions and whilst also negating
the potential effects of white-coat hypertension. Finally, it has been speculated that the
positive effects of anthocyanin rich supplementation such as Montmorency tart cherries
or blueberries on cardiometabolic health are mediated via anti-inflammatory, antioxidant
and nitric oxide promoting effects. However, owing to time and cost implications, the
proposed investigation will not examine pathophysiological biomarkers, meaning that
the mechanistic bases for any improvements in cardiometabolic parameters will not be
elucidated. Improved understanding of the mechanistic influence of anthocyanin rich
supplementation on cardiovascular and metabolic health makes the expectation tenable
that they can be better exploited in order to improve cardiometabolic health throughout
lifespans. Therefore, future investigations beyond the study protocol described here should
seek to explore and utilize the mechanistic pathways of Montmorency tart cherry and
blueberry supplementation.
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